SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : genelabs(gnlb)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Amigo Mike who wrote (223)4/13/2001 2:41:17 PM
From: Toni Wheeler  Read Replies (1) of 233
 
Is it time to seek that PAYDIRT??

Hi, Amigo Mike and Texas Dude, I think the time for GNLB is nigh!

FDA Advisory Committee meeting on Aslera is scheduled next week on the 19th....we should know something one way or the other...? These are 'tricky' times for investors, IMO, and I think the present stock price reflects that uncertainty.

If positively passed out of the committee, June 26th [or before] is the next date to look for final FDA notification/approval.

In the meantime, with perfect timing <gg> [perhaps a lil peek at future products?], Genelabs has been issued a long awaited patent:


delphion.com

Inventor(s): Fuerst; Thomas R. , San Antonio, TX
McAtee; C. Patrick , San Jose, CA
Yarbough; Patrice O. , Union City, CA
Zhang; Yi-Fan , Mountain View, CA

Applicant(s): Genelabs Technologies, Inc., Redwood City, CA
News, Profiles, Stocks and More about this company

Issued/Filed Dates: April 10, 2001 / Oct. 13, 1995

Application Number: US1995000542634

IPC Class: C07K 14/08;

Class: 530/350; 435/005;

Field of Search: 424/189.1 530/806,810,826,350 536/23.72 435/320.1,5,69.3

Abstract:
: Antigens are provided which are derived from the enterically transmitted non-A/non-B viral hepatitis agent, known as hepatitis E virus (HEV). The HEV antigens and in particular, soluble species of the capsid protein encoded by the carboxy terminal region of HEV ORF2, are immunoreactive with sera from individuals infected with HEV. In one embodiment, these antigens may be produced by a baculovirus expression vector and form virus-like particles (VLPs). The antigens are useful as diagnostic reagents in diagnostic methods and kits for determining infection of an individual with HEV. The antigens are also useful in vaccine compositions effective in methods for preventing HEV infection.

Attorney, Agent, or Firm: Fabian; Gary R.; Sholtz; Charles K.; Petithory; Joanne R.;

Primary/Assistant Examiners: Wortman; Donna;


Related Applications:Application Number ApplDate Patent Issued Title
US1994000240049 1994-05-09 US5686239 1997-11-11 Hepatitis E virus peptides and methods
US1992000876941 1992-05-01 US5885768 1999-03-23 Hepatitis E virus peptide antigen and antibodies

* * * * * *
FYI: Sites for info on Hepatitis E Virus

hepatitis.about.com

My best,
T.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext